

Index

- Abalovich, M., Llesuy, S., Gutierrez, S. & Repetto, M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments: 321
- Adami, S. *see* Zoico, E.
- Agranovicz, S. *see* Krausz, Y.
- Agretti, P. *see* Tonacchera, M.
- Ahrén, B. *see* Bülow, B.
- Aimaretti, G. *see* Popovic, V.
- Aimaretti, G., Corneli, G., Baldelli, R., Di Somma, C., Gasco, V., Durante, C., Ausiello, L., Rovere, S., Grottoli, S., Tamburrano, G. & Ghigo, E. Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency: 56
- Akada, K. *see* Nishioka, H.
- Alessi, E. *see* Verga, U.
- Alevizaki, C.C. *see* Alevizaki, M.
- Alevizaki, M., Cimponeriu, A.T., Garofallaki, M., Sarika, H.-L., Alevizaki, C.C., Papamichael, C., Philippou, G., Anastasiou, E.A., Lekakis, J.P. & Mavrikakis, M. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men: 749
- Altunbas, H. *see* Sari, R.
- Alvarez, P., Isidro, L., Peinó, R., Leal-Cerro, A., Casanueva, F.F., Dieguez, C. & Cordido, F. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients: 431
- Amato, G. *see* Mazziotti, G.
- Ambrogini, E. *see* Tonacchera, M.
- Anastasiou, E.A. *see* Alevizaki, M.
- de Andrés-Aguayo, I. *see* Webb, S.M.
- Antunes-Rodrigues, J. *see* Elias, P.C.L.
- Anyaku, V. *see* Kousta, E.
- Arai, K. *see* Kim, K.
- Arena, S. *see* Florio, T.
- Arends, N.J.T., Boonstra, V.H., Mulder, P.G.H., Odink, R.J.H., Stokvis-Brantsma, W.H., Rongen-Westerlaken, C., Mulder, J.C., Delemarre-Van de Waal, H., Reeser, H.M., Jansen, M., Waelkens, J.J.J. & Hokken-Koelega, A.C.S. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial: 779
- Armitage, M., Nooney, J. & Evans, S. Recent concerns surrounding HRT: 145
- Arnaldi, G. *see* Kola, B.
- Arnhold, I.J.P. *see* Carvalho, L.R.
- Arnold, A. *see* Shattuck, T.M.
- Arosio, M. *see* Giavoli, C.
- Arp, P. *see* van Rossum, E.F.C.
- Arvat, E. *see* Gianotti, L.
- Arvat, E. *see* Giordano, R.
- Asenbaum, S. *see* Zetting, G.
- Assies, J., Haverkort, E.B., Lieverse, R. & Vreken, P. Effect of dehydroepiandrosterone supplementation on fatty acid and hormone levels in patients with X-linked adrenoleucodystrophy: 459
- Astuti, D., Hart-Holden, N., Latif, F., Laloo, F., Black, G.C., Lim, C., Moran, A., Grossman, A.B., Hodgson, S.V., Freemont, A., Ramsden, R., Eng, C., Evans, D.G.R. & Maher, E.R. Genetic analysis of mitochondrial complex II subunits *SDHD*, *SDHB* and *SDHC* in paraganglioma and pheochromocytoma susceptibility: 728
- Ausiello, L. *see* Aimaretti, G.
- Ávila, A. *see* Bazaes, R.A.
- van Baar, A.L. *see* Pop, V.J.
- Badenhoop, K. & Seidl, C. Fine-tuning of T lymphocytes in autoimmunity: genetic association of CTLA-4 variants and Graves' disease revisited: 555
- Balci, M.K. *see* Cakir, M.
- Balci, M.K. *see* Sari, R.
- Balci, N. *see* Cakir, M.
- Baldelli, R. *see* Aimaretti, G.
- Baldelli, R., Battista, C., Leonetti, F., Ghiggi, M.-R., Ribaudo, M.-C., Paoloni, A., D'Amico, E., Ferretti, E., Baratta, R., Liuzzi, A., Trischitta, V. & Tamburrano, G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment: 492
- Baratta, R. *see* Baldelli, R.
- Barbieri, F. *see* Florio, T.
- Bar-Shalom, R. *see* Krausz, Y.
- Battista, C. *see* Baldelli, R.
- Baudin, E. *see* Gussi, I.-L.
- Bazaes, R.A., Petry, C.J., Ong, K.K., Ávila, A., Dunger, D.B. & Méricq, M.V. Insulin gene VNTR genotype is associated with insulin sensitivity and secretion in infancy: 599
- Beckett, G.J. *see* Strachan, M.W.J.
- Beck-Peccoz, P. *see* Fugazzola, L.
- Beck-Peccoz, P. *see* Giavoli, C.
- Beck-Peccoz, P. *see* Verga, U.
- Bednarczuk, T., Placha, G., Jazdzewski, K., Kurylowicz, A., Kloza, M., Makowska, U., Hiromatsu, Y. & Nauman, J. Interleukin-13 gene polymorphisms in patients with Graves' disease: 519
- van den Beld, A.W. *see* van Rossum, E.F.C.
- Bellanné-Chantelot, C. *see* Roussel, R.
- Bellastella, A. *see* De Bellis, A.

Index

- Abalovich, M., Llesuy, S., Gutierrez, S. & Repetto, M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments: 321
- Adami, S. *see* Zoico, E.
- Agranovicz, S. *see* Krausz, Y.
- Agretti, P. *see* Tonacchera, M.
- Ahrén, B. *see* Bülow, B.
- Aimaretti, G. *see* Popovic, V.
- Aimaretti, G., Corneli, G., Baldelli, R., Di Somma, C., Gasco, V., Durante, C., Ausiello, L., Rovere, S., Grottoli, S., Tamburrano, G. & Ghigo, E. Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency: 56
- Akada, K. *see* Nishioka, H.
- Alessi, E. *see* Verga, U.
- Alevizaki, C.C. *see* Alevizaki, M.
- Alevizaki, M., Cimponeriu, A.T., Garofallaki, M., Sarika, H.-L., Alevizaki, C.C., Papamichael, C., Philippou, G., Anastasiou, E.A., Lekakis, J.P. & Mavrikakis, M. The androgen receptor gene CAG polymorphism is associated with the severity of coronary artery disease in men: 749
- Altunbas, H. *see* Sari, R.
- Alvarez, P., Isidro, L., Peinó, R., Leal-Cerro, A., Casanueva, F.F., Dieguez, C. & Cordido, F. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients: 431
- Amato, G. *see* Mazziotti, G.
- Ambrogini, E. *see* Tonacchera, M.
- Anastasiou, E.A. *see* Alevizaki, M.
- de Andrés-Aguayo, I. *see* Webb, S.M.
- Antunes-Rodrigues, J. *see* Elias, P.C.L.
- Anyaku, V. *see* Kousta, E.
- Arai, K. *see* Kim, K.
- Arena, S. *see* Florio, T.
- Arends, N.J.T., Boonstra, V.H., Mulder, P.G.H., Odink, R.J.H., Stokvis-Brantsma, W.H., Rongen-Westerlaken, C., Mulder, J.C., Delemarre-Van de Waal, H., Reeser, H.M., Jansen, M., Waelkens, J.J.J. & Hokken-Koelega, A.C.S. GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial: 779
- Armitage, M., Nooney, J. & Evans, S. Recent concerns surrounding HRT: 145
- Arnaldi, G. *see* Kola, B.
- Arnhold, I.J.P. *see* Carvalho, L.R.
- Arnold, A. *see* Shattuck, T.M.
- Arosio, M. *see* Giavoli, C.
- Arp, P. *see* van Rossum, E.F.C.
- Arvat, E. *see* Gianotti, L.
- Arvat, E. *see* Giordano, R.
- Asenbaum, S. *see* Zetting, G.
- Assies, J., Haverkort, E.B., Lieverse, R. & Vreken, P. Effect of dehydroepiandrosterone supplementation on fatty acid and hormone levels in patients with X-linked adrenoleucodystrophy: 459
- Astuti, D., Hart-Holden, N., Latif, F., Laloo, F., Black, G.C., Lim, C., Moran, A., Grossman, A.B., Hodgson, S.V., Freemont, A., Ramsden, R., Eng, C., Evans, D.G.R. & Maher, E.R. Genetic analysis of mitochondrial complex II subunits *SDHD*, *SDHB* and *SDHC* in paraganglioma and pheochromocytoma susceptibility: 728
- Ausiello, L. *see* Aimaretti, G.
- Ávila, A. *see* Bazaes, R.A.
- van Baar, A.L. *see* Pop, V.J.
- Badenhoop, K. & Seidl, C. Fine-tuning of T lymphocytes in autoimmunity: genetic association of CTLA-4 variants and Graves' disease revisited: 555
- Balci, M.K. *see* Cakir, M.
- Balci, M.K. *see* Sari, R.
- Balci, N. *see* Cakir, M.
- Baldelli, R. *see* Aimaretti, G.
- Baldelli, R., Battista, C., Leonetti, F., Ghiggi, M.-R., Ribaudo, M.-C., Paoloni, A., D'Amico, E., Ferretti, E., Baratta, R., Liuzzi, A., Trischitta, V. & Tamburrano, G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment: 492
- Baratta, R. *see* Baldelli, R.
- Barbieri, F. *see* Florio, T.
- Bar-Shalom, R. *see* Krausz, Y.
- Battista, C. *see* Baldelli, R.
- Baudin, E. *see* Gussi, I.-L.
- Bazaes, R.A., Petry, C.J., Ong, K.K., Ávila, A., Dunger, D.B. & Méricq, M.V. Insulin gene VNTR genotype is associated with insulin sensitivity and secretion in infancy: 599
- Beckett, G.J. *see* Strachan, M.W.J.
- Beck-Peccoz, P. *see* Fugazzola, L.
- Beck-Peccoz, P. *see* Giavoli, C.
- Beck-Peccoz, P. *see* Verga, U.
- Bednarczuk, T., Placha, G., Jazdzewski, K., Kurylowicz, A., Kloza, M., Makowska, U., Hiromatsu, Y. & Nauman, J. Interleukin-13 gene polymorphisms in patients with Graves' disease: 519
- van den Beld, A.W. *see* van Rossum, E.F.C.
- Bellanné-Chantelot, C. *see* Roussel, R.
- Bellastella, A. *see* De Bellis, A.

- de Bellis, A., Bizzarro, A., Conte, M., Coronella, C., Solimeno, S., Perrino, S., Sansone, D., Guaglione, M., Wall, J.R. & Bellastella, A. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy: 388
- Ben-Dov, I., Gaides, M., Scheinowitz, M., Wagner, R. & Laron, Z. Reduced exercise capacity in untreated adults with primary growth hormone resistance (Laron syndrome): 763
- van Beneden, R. *see* Donckier, J.E.
- Bengtsson, B.Å. *see* Leonsson, M.
- Ben-Shlomo, Y., Holly, J., McCarthy, A., Savage, P., Davies, D., Gunnell, D. & Smith, G.D. An investigation of fetal, post-natal and childhood growth with insulin-like growth factor I and binding protein 3 in adulthood: 366
- Berselli, M.E. *see* Di Blasio, A.M.
- Bhatia, E. *see* Nigam, R.
- Bidart, J.M. *see* Gussi, I.-L.
- Bifulco, G. *see* Tommaselli, G.A.
- Billadello, J.J. *see* Landt, M.
- Bissoli, L. *see* Zoico, E.
- Bitti, M.L.M. *see* Tonacchera, M.
- Bizzarro, A. *see* De Bellis, A.
- Black, G.C. *see* Astuti, D.
- Bocca, L. *see* Florio, T.
- Bocher, M. *see* Krausz, Y.
- Bogazzi, F. *see* Cecconi, E.
- Boivin, C.M. *see* Shaw, N.J.
- Boonstra, V.H. *see* Arends, N.J.T.
- Boscaro, M. *see* Kola, B.
- Bosello, O. *see* Zoico, E.
- Boutignon, F. *see* Gianotti, L.
- Brabant, G. *see* Parkinson, C.
- Bradley, C. *see* McMillan, C.V.
- van den Brink, C.E. *see* Vermeer, H.
- Brinkmann, A.O. *see* van Rossum, E.F.C.
- Brixen, K. *see* Gravholt, C.H.
- Brossa, P. *see* Giordano, R.
- Brouwers, E.P. *see* Pop, V.J.
- Brown, L. *see* Tomasi, P.A.
- Brozzetti, A. *see* Nigam, R.
- Bülow, B., Åhrén, B., Fisker, S., Dehlin, O., Hagberg, B., Jensen, E., Svensson, T., Samuelsson, G. & Erfurth, E.M. The gender differences in growth hormone-binding protein and leptin persist in 80-year-old men and women and is not caused by sex hormones: 482
- Buongiorno, A.M. *see* Lucia, P.
- van der Burg, B. *see* Vermeer, H.
- van Buul-Offers, S.C. *see* Vermeer, H.
- Bustin, S. *see* Kola, B.
- Buzi, F. *see* Radetti, G.
- Caiola, S. *see* Lucia, P.
- Cakir, M., Samanci, N., Balci, N. & Balci, M.K. Musculoskeletal manifestations in patients with thyroid disease: 162
- Calderan, A. *see* Opocher, G.
- Camargo-Neto, E. *see* Kreisner, E.
- Cambiaghi, S. *see* Verga, U.
- Cappiello, V. *see* Giavoli, C.
- Capuano, E. *see* Mazziotti, G.
- Capuano, G. *see* Mattera, D.
- Capuano, S. *see* Mazziotti, G.
- Carbone, A. *see* Mazziotti, G.
- Carella, C. *see* Mazziotti, G.
- Carroll, P.V. *see* Swords, F.M.
- Carvalho, L.R., de Faria, M.E.J., Farah Osorio, M.G., Estefan, V., Lima Jorge, A.A., Arnhold, I.J.P. & Mendonça, B.B. Acromegalic features in Growth hormone (GH)-deficient patients after long-term GH therapy: 788
- Casamitjana, R. *see* Webb, S.M.
- Casanueva, F.F. *see* Alvarez, P.
- Casanueva, F.F. *see* Popovic, V.
- Cassar, W. *see* Radetti, G.
- Castagna, M.G. *see* Vermiglio, F.
- Castro, M. *see* Elias, P.C.L.
- Castro, M., Elias, L.L.K., Elias, P.C.L. & Moreira, A.C. A dose-response study of salivary cortisol after dexamethasone suppression test in Cushing's disease and its potential use in the differential diagnosis of Cushing's syndrome: 800
- Ceccarelli, C. *see* Tonacchera, M.
- Cecconi, E., Bogazzi, F., Cetani, F., Grasso, L., Marcocci, C., Genovesi, M., Procopio, M., Gasperi, M., Pinchera, A., Ghigo, E. & Martino, E. Impaired GH secretion to provocative stimuli in two families with hypocalcaemic hypercalcaemia: 604
- Cela, E. *see* Kousta, E.
- Celermajer, D.S. *see* Sader, M.A.
- Cetani, F. *see* Cecconi, E.
- Chaganti, R.S.K. *see* Shattuck, T.M.
- Chan, J.C.N. *see* Ma, Y.Q.
- Chanson, P. *see* Gussi, I.-L.
- Chiovato, L. *see* Tonacchera, M.
- Chisin, R. *see* Krausz, Y.
- Christiansen, J.S. *see* Gravholt, C.H.
- Cimponeriu, A.T. *see* Alevizaki, M.
- Čirić, J. *see* Žarković, M.
- Cittadini, A. *see* Saccà, L.
- Clark, O.H. *see* Shattuck, T.M.
- Clark, P. *see* Weedon, M.N.
- Clayton, P.E. *see* Parkinson, C.
- Clayton, P.E. *see* Whatmore, A.J.
- Cockram, C.S. *see* Ma, Y.Q.

- Codoceo, R. *see* Iglesias, P.
 Colantuoni, V. *see* Mancini, F.P.
 Colao, A. *see* Mittera, D.
 Columb, B. *see* Mukherjee, A.
 Contaldo, F. *see* Mancini, F.P.
 Conte, M. *see* De Bellis, A.
 Coppola, A. *see* Lucia, P.
 Cordido, F. *see* Alvarez, P.
 Corneli, G. *see* Aimaretti, G.
 Corneli, G. *see* Popovic, V.
 Coronella, C. *see* De Bellis, A.
 Corsaro, A. *see* Florio, T.
 Cortelazzi, D. *see* Verga, U.
 Costa, J. *see* Shattuck, T.M.
 Crabtree, N.J. *see* Shaw, N.J.
 Crawford, L. *see* McKenzie, J.
 Cridland, J.C. *see* Johnstone, A.P.
 Critchley, J.A.J.H. *see* Ma, Y.Q.
 Crown, A. *see* Levy, A.
 Cziráj, S. *see* Kola, B.
 D'Agostino, L. *see* Mittera, D.
 D'Amico, E. *see* Baldelli, R.
 Da Costa, C.R. *see* Johnstone, A.P.
 Dacie, J.E. *see* Kaltsas, G.A.
 Damjanovic, S. *see* Popovic, V.
 Dan, S. *see* Lazar, L.
 Davies, D. *see* Ben-Shlomo, Y.
 Davies, J.S. *see* Pinto, L.P.
 Deghenghi, R. *see* Gianotti, L.
 Dehlin, O. *see* Bülow, B.
 Deiguez, C. *see* Popovic, V.
 Delemarre-Van de Waal, H. *see* Arends, N.J.T.
 Delitala, G. *see* Tomasi, P.A.
 Delos, M. *see* Donckier, J.E.
 Destefanis, S. *see* Gianotti, L.
 Destefanis, S. *see* Giordano, R.
 Di Blasio, A.M., van Rossum, E.F.C., Maestrini, S., Berselli, M.E., Tagliaferri, M., Podestà, F., Koper, J.W., Liuzzi, A. & Lamberts, S.W.J. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients: 68
 Di Carlo, C. *see* Tommaselli, G.A.
 Di Somma, C. *see* Aimaretti, G.
 Di Spizio Sardo, A. *see* Tommaselli, G.A.
 Diana, F. *see* Florio, T.
 Diaz-Cano, S. *see* Kola, B.
 Dieguez, C. *see* Alvarez, P.
 Diemling, M. *see* Zettinig, G.
 Diez, J.J. *see* Iglesias, P.
 Dohle, G.R. *see* de Gouveia Brazao, C.A.
 Doknic, M. *see* Popovic, V.
 Donckier, J.E., Michel, L., Van Beneden, R., Delos, M. & Havaux, X. Increased expression of endothelin-1 and its mitogenic receptor ET_A in human papillary thyroid carcinoma: 354
 Don-Wauchope, A.C. *see* Strachan, M.W.J.
 Drake, W.M. *see* Parkinson, C.
 Dubois-Laforgue, D. *see* Roussel, R.
 Dudczak, R. *see* Zettinig, G.
 Dunger, D. *see* Potau, N.
 Dunger, D.B. *see* Bazaes, R.A.
 Durante, C. *see* Aimaretti, G.
 Eisenbarth, G.S. *see* Nigam, R.
 Elias, L.L.K. *see* Castro, M.
 Elias, L.L.K. *see* Elias, P.C.L.
 Elias, P.C.L. *see* Castro, M.
 Elias, P.C.L., Elias, L.L.K., Torres, N., Moreira, A.C., Antunes-Rodrigues, J. & Castro, M. Progressive decline of vasopressin secretion in familial autosomal dominant neurohypophyseal diabetes insipidus presenting a novel mutation in the vasopressin-neurophysin II gene: 511
 Elisei, R. *see* Tonacchera, M.
 Ellis, J.A. & Harrap, S.B. Tall stories: the devilish detail of genetic association studies: 278
 Elneceve, R.H. *see* Mainieri, A.S.
 Emoto, M. *see* Nagasaki, T.
 Endert, E. *see* Strieder, T.G.A.
 Eng, C. *see* Astuti, D.
 Engel, A. *see* Krausz, Y.
 Epaminonda, P. *see* Giavoli, C.
 Erenpreiss, Y. *see* de Gouveia Brazao, C.A.
 Erfurth, E.M. *see* Bülow, B.
 Estefan, V. *see* Carvalho, L.R.
 Ester, W. *see* van Rossum, E.F.C.
 Evans, D.G.R. *see* Astuti, D.
 Evans, L.M. *see* Pinto, L.P.
 Evans, S. *see* Armitage, M.
 Even-Sapir, E. *see* Krausz, Y.
 Falorni, A. *see* Nigam, R.
 Farah Osorio, M.G. *see* Carvalho, L.R.
 de Faria, M.E.J. *see* Carvalho, L.R.
 Fernández Pérez, C. *see* González Sánchez, J.L.
 Ferrante, E. *see* Giavoli, C.
 Ferretti, E. *see* Baldelli, R.
 Fidalgo, P.A. *see* Iglesias, P.
 Finelli, C. *see* Mancini, F.P.
 Finocchiaro, M.D. *see* Vermiglio, F.
 Fisker, S. *see* Bülow, B.
 Florio, T., Thellung, S., Corsaro, A., Bocca, L., Arena, S., Pattarozzi, A., Villa, V., Massa, A., Diana, F., Schettini, D., Barbieri, F., Ravetti, J.L., Spaziante, R., Giusti, M. & Schettini, G. Characterization of the intracellular mechanisms

- mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells *in vitro*: 115
- Foy, P. *see* Malik, I.A.
- Fraser, N.C. *see* Shaw, N.J.
- Frayling, T.M. *see* Weedon, M.N.
- Freaney, R. *see* Suliman, A.M.
- Freemont, A. *see* Astuti, D.
- Fueger, B.J. *see* Zettinig, G.
- Fugazzola, L. *see* Verga, U.
- Fugazzola, L., Persani, L., Mannavola, D., Reschini, E., Vannucchi, G., Weber, G. & Beck-Peccoz, P. Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement: 230
- Fujiwara, S. *see* Nagasaki, T.
- Furuhashi, M., Ura, N., Higashiura, K., Murakami, H. & Shimamoto, K. Circulating resistin levels in essential hypertension: 507
- Fuse, Y., Igari, T., Yamada, C., Sakano, S., Ito, H., Umenai, T. & Irie, M. Epidemiological survey of thyroid volume and iodine intake in schoolchildren, postpartum women and neonates living in Ulaan Baatar: 298
- Gai, V. *see* Tassone, F.
- Gaides, M. *see* Ben-Dov, I.
- Gallacher, S. *see* McKenzie, J.
- Gallardo, E. *see* Webb, S.M.
- Gangi, E. *see* Verga, U.
- Garofallaki, M. *see* Alevisaki, M.
- Gasco, V. *see* Aimaretti, G.
- Gasperi, M. *see* Cecconi, E.
- Gaz, R.D. *see* Shattuck, T.M.
- Genovesi, M. *see* Cecconi, E.
- Ghiggi, M.-R. *see* Baldelli, R.
- Ghigo, E. *see* Aimaretti, G.
- Ghigo, E. *see* Cecconi, E.
- Ghigo, E. *see* Gianotti, L.
- Ghigo, E. *see* Giordano, R.
- Ghigo, E. *see* Popovic, V.
- Ghigo, E. *see* Tassone, F.
- Gianotti, L. *see* Giordano, R.
- Gianotti, L. *see* Tassone, F.
- Gianotti, L., Veldhuis, J.D., Destefanis, S., Lanfranco, F., Ramunni, J., Arvat, E., Marzetto, M., Boutignon, F., Deghenghi, R. & Ghigo, E. Suppression and recovery of LH secretion by a potent and selective GnRH-receptor antagonist peptide in healthy early follicular-phase women are mediated via selective control of LH secretory burst mass: 526
- Giavoli, C., Porretti, S., Ferrante, E., Cappiello, V., Ronchi, C.L., Travaglini, P., Epaminonda, P., Arosio, M. & Beck-Peccoz, P. Recombinant hGH replacement therapy and the hypothalamus-pituitary-thyroid axis in children with GH deficiency: when should we be concerned about the occurrence of central hypothyroidism?: 806
- Gibney, J. *see* McMillan, C.V.
- Giordano, R., Grottoli, S., Brossa, P., Pellegrino, M., Destefanis, S., Lanfranco, F., Gianotti, L., Ghigo, E. & Arvat, E. Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans: 314
- Giusti, M. *see* Florio, T.
- Gleeson, H.K. *see* Mukherjee, A.
- Gligorović, P.V. *see* Žarković, M.
- Godsland, I.F. *see* Kousta, E.
- González Sánchez, J.L., Proenza, A.M., Martínez Larrad, M.T., Ramis, J.M., Fernández Pérez, C., Palou, A. & Serrano Ríos, M. The glutamine 27 glutamic acid polymorphism of the β_2 -adrenoceptor gene is associated with abdominal obesity and greater risk of impaired glucose tolerance in men but not in women: a population-based study in Spain: 476
- Gough, S.C.L. *see* Tait, K.F.
- de Gouveia Brazao, C.A., Pierik, F.H., Erenpreiss, Y., de Jong, F.H., Dohle, G.R. & Weber, R.F.A. The effect of cryptorchidism on inhibin B in a subfertile population: 136
- Granberg, D., Sundin, A., Janson, E.T., Öberg, K., Skogseid, B. & Westlin, J.-E. Octreoscan in patients with bronchial carcinoid tumours: 793
- Grasso, L. *see* Cecconi, E.
- Gravholt, C.H., Vestergaard, P., Hermann, A.P., Mosekilde, L., Brixen, K. & Christiansen, J.S. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey: 89
- Greer, I.A. *see* McKenzie, J.
- Griffiths, K.A. *see* Sader, M.A.
- Grobbee, D.E. *see* van Rossum, E.F.C.
- Gross, J.L. *see* Kreisner, E.
- Grossman, A.B. *see* Astuti, D.
- Grossman, A.B. *see* Kaltsas, G.A.
- Grossman, A.B. *see* Kola, B.
- Grottoli, S. *see* Aimaretti, G.
- Grottoli, S. *see* Giordano, R.
- Grottoli, S. *see* Tassone, F.
- Guaglione, M. *see* De Bellis, A.
- Gunnell, D. *see* Ben-Shlomo, Y.
- Gupta, N. *see* Marwaha, R.K.
- Gurnell, M. PPAR γ and metabolism: insights from the study of human genetic variants: 267
- Gussi, I.-L., Young, J., Baudin, E., Bidart, J.M. & Chanson, P. Chromogranin A as serum marker of pituitary adenomas: 644
- Gutierrez, S. *see* Abalovich, M.
- Hagberg, B. *see* Bülow, B.

- Hall, C.M. *see* Whatmore, A.J.
 Handelsman, D.J. *see* Sader, M.A.
 Hanna, F.W.F. *see* Pinto, L.P.
 Hanson, J.A. *see* Kaltsas, G.A.
 Harada, S. *see* Kotani, T.
 Haraoka, J. *see* Nishioka, H.
 Harrap, S.B. *see* Ellis, J.A.
 Hart-Holden, N. *see* Astuti, D.
 Hattersley, A.T. *see* Weedon, M.N.
 Havaux, X. *see* Donckier, J.E.
 Haverkort, E.B. *see* Assies, J.
 Hayakawa, T. *see* Tanaka, K.
 Healy, M.L. *see* McMillan, C.V.
 Hendriks-Stegeman, B.I. *see* Vermeer, H.
 Henmi, Y. *see* Nagasaki, T.
 Hermann, A.P. *see* Gravholt, C.H.
 Higashiura, K. *see* Furuhashi, M.
 Hiromatsu, Y. *see* Bednarczuk, T.
 Hishinuma, A. *see* Kotani, T.
 Ho, K.K.Y. *see* Nugent, A.G.
 Hodgson, S.V. *see* Astuti, D.
 Hofmann, A. *see* Zettinig, G.
 Hokken-Koelega, A.C.S. *see* Arends, N.J.T.
 Hollenberg, A. *see* Shattuck, T.M.
 Holly, J. *see* Ben-Shlomo, Y.
 Hulthe, J. *see* Leonsson, M.
 Ibáñez, L. *see* Potau, N.
 Ieiri, T. *see* Kotani, T.
 Igari, T. *see* Fuse, Y.
 Iglesias, P., Fidalgo, P.A., Codoceo, R. & Díez, J.J. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function: 621
 Illa, I. *see* Webb, S.M.
 Imanishi, Y. *see* Shattuck, T.M.
 Inaba, M. *see* Nagasaki, T.
 Iorio, S. *see* Mazziotti, G.
 Irie, M. *see* Fuse, Y.
 Ishii, N. *see* Tanaka, K.
 Ishikawa, T. *see* Nagasaki, T.
 Ishimura, E. *see* Nagasaki, T.
 Isidori, A.M. *see* Kaltsas, G.A.
 Isidro, L. *see* Alvarez, P.
 Israel, O. *see* Krausz, Y.
 Ito, H. *see* Fuse, Y.
 Ivočić, M.S. *see* Žarković, M.
 Jaap, A.J. *see* McKenzie, J.
 Jansen, M. *see* Arends, N.J.T.
 Jansen, M. *see* Vermeer, H.
 Janson, E.T. *see* Granberg, D.
 Janssen, J.A.M.J.L. *see* van Rossum, E.F.C.
 Jayasinghe, A. *see* Okosieme, O.E.
 Jazdzewski, K. *see* Bednarczuk, T.
 Jensen, E. *see* Bülow, B.
 Johannsson, G. *see* Leonsson, M.
 John, R. *see* Pinto, L.P.
 Johnston, D.G. *see* Kousta, E.
 Johnstone, A.P., Cridland, J.C., Da Costa, C.R., Nussey, S.S. & Shepherd, P.S. A functional site on the human TSH receptor: a potential therapeutic target in Graves' disease: 437
 Jones, J. *see* Whatmore, A.J.
 de Jong, F.H. *see* de Gouveia Brazao, C.A.
 de Jong, F.H. *see* van Rossum, E.F.C.
 Jönsson, P. *see* Lissett, C.A.
 Jordan, S. *see* Kola, B.
 Kaltsas, G. *see* Kola, B.
 Kaltsas, G.A., Mukherjee, J.J., Kola, B., Isidori, A.M., Hanson, J.A., Dacie, J.E., Reznick, R., Monson, J.P. & Grossman, A.B. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?: 34
 Karak, A.K. *see* Marwaha, R.K.
 Karayalcin, U. *see* Sari, R.
 Kawano, J. *see* Kotani, T.
 Keidar, Z. *see* Krausz, Y.
 Kelly, A. *see* McKenzie, J.
 Kelnar, C.J.H. Growth hormone therapy for syndromic disorders: 12
 Kemp, E.H., Metcalfe, R.A., Smith, K.A., Woodroffe, M.N., Watson, P.F. & Weetman, A.P. Detection and localization of chemokine gene expression in autoimmune thyroid disease: 207
 Kilby, M.D. Thyroid hormones and fetal brain development: 280
 Kim, K., Sanno, N., Arai, K., Takano, K., Yasufuku-Takano, J., Teramoto, A. & Shibasaki, T. Ghrelin mRNA and GH secretagogue receptor mRNA in human GH-producing pituitary adenomas is affected by mutations in the α subunit of G protein: 630
 Kim, T.S. *see* Shattuck, T.M.
 Kisalu, J. *see* Swords, F.M.
 Kloza, M. *see* Bednarczuk, T.
 Knight, B. *see* Weedon, M.N.
 Kochupillai, N. *see* Marwaha, R.K.
 Kogan, I. *see* Krausz, Y.
 Kola, B. *see* Kaltsas, G.A.
 Kola, B., Korbonits, M., Diaz-Cano, S., Kaltsas, G., Morris, D.G., Jordan, S., Metherell, L., Powell, M., Cziráj, S., Arnaldi, G., Bustin, S., Boscaro, M., Mantero, F. & Grossman, A.B. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor: 328

- Koper, J.W. *see* Di Blasio, A.M.
- Koper, J.W. *see* van Rossum, E.F.C.
- Korbonits, M. *see* Kola, B.
- Kostić, V. *see* Žarković, M.
- Kotani, T., Umeki, K., Kawano, J., Suganuma, T., Hishinuma, A., Ieiri, T. & Harada, S. Partial iodide organification defect caused by a novel mutation of the thyroid peroxidase gene in three siblings: 198
- Kousta, E., Lawrence, N.J., Godslan, I.F., Penny, A., Anyaoku, V., Millauer, B.A., Cela, E., Johnston, D.G., Robinson, S. & McCarthy, M.I. Insulin resistance and β -cell dysfunction in normoglycaemic European women with a history of gestational diabetes: 289
- Krausz, Y., Keidar, Z., Kogan, I., Even-Sapir, E., Bar-Shalom, R., Engel, A., Rubinstein, R., Sachs, J., Bocher, M., Agranovicz, S., Chisin, R. & Israel, O. SPECT/CT hybrid imaging with ^{111}In -pentetretotide in assessment of neuroendocrine tumours: 565
- Kreisner, E., Camargo-Neto, E., Maia, C.R. & Gross, J.L. Accuracy of ultrasonography to establish the diagnosis and aetiology of permanent primary congenital hypothyroidism: 361
- Kribben, A. *see* Witzke, O.
- Krohn, K. *see* Miedlich, S.
- Kumeda, Y. *see* Nagasaki, T.
- Kurylowicz, A. *see* Bednarczuk, T.
- Laloo, F. *see* Astuti, D.
- Lam, K.S.L. *see* Tan, K.C.B.
- Lam, K.S.L. *see* Tso, A.W.K.
- Lamberts, S.W.J. *see* Di Blasio, A.M.
- Lamberts, S.W.J. *see* van Rossum, E.F.C.
- Landt, M., Ludbrook, P.A. & Billadello, J.J. Role of protein binding in renal elimination of leptin: 44
- Lanfranco, F. *see* Gianotti, L.
- Lanfranco, F. *see* Giordano, R.
- Lanfranco, F. *see* Tassone, F.
- Laron, Z. *see* Ben-Dov, I.
- Larsson, C. *see* Tso, A.W.K.
- Latif, F. *see* Astuti, D.
- Lawrence, N.J. *see* Kousta, E.
- Lazar, L., Dan, S. & Phillip, M. Growth without growth hormone: growth pattern and final height of five patients with idiopathic combined pituitary hormone deficiency: 82
- Lazarus, J.H. *see* Okosieme, O.E.
- Leal-Cerro, A. *see* Alvarez, P.
- Lejeune, P.J. *see* Okosieme, O.E.
- Lekakis, J.P. *see* Alevisaki, M.
- Leonetti, F. *see* Baldelli, R.
- Leonsson, M., Hulthe, J., Johannsson, G., Wiklund, O., Wikstrand, J., Bengtsson, B.Å. & Oscarsson, J. Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness: 242
- Leung, K.-C. *see* Nugent, A.G.
- Levy, A., Crown, A. & Reid, R. Endocrine intervention for transsexuals: 409
- Lieverse, R. *see* Assies, J.
- Lim, C. *see* Astuti, D.
- Lim, P.O. & MacDonald, T.M. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension: 427
- Lima Jorge, A.A. *see* Carvalho, L.R.
- Lissett, C.A., Jönsson, P., Monson, J.P. & Shalet, S.M. Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD: 773
- Liuzzi, A. *see* Baldelli, R.
- Liuzzi, A. *see* Di Blasio, A.M.
- Llesuy, S. *see* Abalovich, M.
- Lo Presti, V.P. *see* Vermiglio, F.
- Lo, C.Y. *see* Tso, A.W.K.
- Lowe, G.D. *see* McKenzie, J.
- Lucia, P., Caiola, S., Coppola, A., Manetti, L.L., Maroccia, E., Buongiorno, A.M. & de Martinis, C. Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure?: 723
- Ludbrook, P.A. *see* Landt, M.
- Ma, Y.Q., Thomas, G.N., Ng, M.C.Y., Critchley, J.A.J.H., Cockram, C.S., Chan, J.C.N. & Tomlinson, B. Association of two apolipoprotein A-I gene *MspI* polymorphisms with high density lipoprotein (HDL)-cholesterol levels and indices of obesity in selected healthy Chinese subjects and in patients with early-onset type 2 diabetes: 442
- Maccario, M. *see* Tassone, F.
- MacDonald, T.M. *see* Lim, P.O.
- MacFarlane, I.A. *see* Malik, I.A.
- Macut, D. *see* Žarković, M.
- Maestrini, S. *see* Di Blasio, A.M.
- Maghnie, M. *see* Radetti, G.
- Maher, E.R. *see* Astuti, D.
- Maia, C.R. *see* Kreisner, E.
- Mainieri, A.S. & Elneave, R.H. Usefulness of the free α -subunit to diagnose hypogonadotropic hypogonadism: 307
- Makowska, U. *see* Bednarczuk, T.
- Malik, I.A., Foy, P., Wallymahmed, M., Wilding, J.P.H. & Macfarlane, I.A. Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects: 75
- Mancini, F.P., Sabatino, L., Colantuoni, V., Pasanisi, F., Finelli, C., Contaldo, F., Masulli, M., Riccardi, G. & Vaccaro, O. Variants of uncoupling protein-2 gene and obesity: interaction with peroxisome proliferator-activated receptor2: 817

- Mandolino, M. *see* Vermiglio, F.
 Manetti, L.L. *see* Lucia, P.
 Manguso, F. *see* Mattered, D.
 Mann, K. *see* Witzke, O.
 Mannavola, D. *see* Fugazzola, L.
 Mantero, F. *see* Kola, B.
 Mantero, F. *see* Opocher, G.
 de Marco, G. *see* Tonacchera, M.
 Marcocci, C. *see* Cecconi, E.
 Maroccia, E. *see* Lucia, P.
 Martínez Larrad, M.T. *see* González Sánchez, J.L.
 Martella, M. *see* Opocher, G.
 de Martinis, C. *see* Lucia, P.
 Martino, E. *see* Cecconi, E.
 Marwaha, R.K., Tandon, N., Gupta, N., Karak, A.K., Verma, K. & Kochupillai, N. Residual goitre in the postiodization phase: iodine status, thiocyanate exposure and autoimmunity: 672
 Marzetto, M. *see* Gianotti, L.
 Massa, A. *see* Florio, T.
 Masulli, M. *see* Mancini, F.P.
 Mattered, D., Capuano, G., Colao, A., Pivonello, R., Manguso, F., Puziello, A. & D'Agostino, L. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma: 699
 Mattina, F. *see* Vermiglio, F.
 Mavrikakis, M. *see* Alevizaki, M.
 Mazzali, G. *see* Zoico, E.
 Mazziotti, G., Sorvillo, F., Iorio, S., Carbone, A., Romeo, A., Piscopo, M., Capuano, S., Capuano, E., Amato, G. & Carella, C. Grey-scale analysis allows a quantitative evaluation of thyroid echogenicity in the patients with Hashimoto's thyroiditis: 223
 McBrinn, Y. *see* Suliman, A.M.
 McCarthy, A. *see* Ben-Shlomo, Y.
 McCarthy, M.I. *see* Kousta, E.
 McKenna, T.J. *see* Suliman, A.M.
 McKenzie, J., Jaap, A.J., Gallacher, S., Kelly, A., Crawford, L., Greer, I.A., Rumley, A., Petrie, J.R., Lowe, G.D., Paterson, K. & Sattar, N. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?: 682
 McMillan, C.V., Bradley, C., Gibney, J., Healy, M.L., Russell-Jones, D.L. & Sönksen, P.H. Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency: 467
 Mendonca, B.B. *see* Carvalho, L.R.
 Mericq, M.V. *see* Bazaes, R.A.
 Mestrón, A. *see* Webb, S.M.
 Metcalfe, R.A. *see* Kemp, E.H.
 Metherell, L. *see* Kola, B.
 Miao, D. *see* Nigam, R.
 Michel, L. *see* Donckier, J.E.
 Micic, D. *see* Popovic, V.
 Miedlich, S., Krohn, K. & Paschke, R. Update on genetic and clinical aspects of primary hyperparathyroidism: 539
 Millauer, B.A. *see* Kousta, E.
 Mittlboeck, M. *see* Zettinig, G.
 Mizuguchi, H. *see* Tanaka, K.
 Moleti, M. *see* Vermiglio, F.
 Monchik, J.M. *see* Shattuck, T.M.
 Monson, J.P. *see* Kaltsas, G.A.
 Monson, J.P. *see* Lissett, C.A.
 Monson, J.P. *see* Swords, F.M.
 Moran, A. *see* Astuti, D.
 Moreira, A.C. *see* Castro, M.
 Moreira, A.C. *see* Elias, P.C.L.
 Morris, D.G. *see* Kola, B.
 Mosekilde, L. *see* Gravholt, C.H.
 Mostacciolo, M.L. *see* Opocher, G.
 Mukherjee, A., Murray, R.D., Columb, B., Gleeson, H.K. & Shalet, S.M. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis: 743
 Mukherjee, J.J. *see* Kaltsas, G.A.
 Mulder, J.C. *see* Arends, N.J.T.
 Mulder, P.G.H. *see* Arends, N.J.T.
 Murakami, H. *see* Furuhashi, M.
 Muranaga, T. *see* Tanaka, M.
 Murgia, A. *see* Opocher, G.
 Murray, B. *see* Suliman, A.M.
 Murray, R.D. *see* Mukherjee, A.
 Nagasaki, T., Inaba, M., Henmi, Y., Kumeda, Y., Ueda, M., Tahara, H., Sugiguchi, S., Fujiwara, S., Emoto, M., Ishimura, E., Onoda, N., Ishikawa, T. & Nishizawa, Y. Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid function: 607
 Nagayama, Y. *see* Tanaka, K.
 Nakahara, T. *see* Tanaka, M.
 Nakao, K. *see* Tanaka, K.
 Nakazato, M. *see* Tanaka, M.
 Napoli, R. *see* Saccà, L.
 Nappi, C. *see* Tommaselli, G.A.
 Naruo, T. *see* Tanaka, M.
 Nauman, J. *see* Bednarczuk, T.
 Navone, F. *see* Tassone, F.
 Ng, M.C.Y. *see* Ma, Y.Q.
 Nigam, R., Bhatia, E., Miao, D., Yu, L., Brozzetti, A., Eisenbarth, G.S. & Falorni, A. Prevalence of adrenal antibodies in Addison's disease among north Indian Caucasians: 593
 Nishioka, H., Haraoka, J. & Akada, K. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin GH-producing pituitary adenomas: 768

- Nishizawa, Y. *see* Nagasaki, T.
 Niwa, M. *see* Tanaka, K.
 Nooney, J. *see* Armitage, M.
 Nozoe, S.-I. *see* Tanaka, M.
 Nugent, A.G., Leung, K.-C., Sullivan, D., Reutens, A.T. & Ho, K.K.Y. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women: 690
 Nussey, S.S. *see* Johnstone, A.P.
 Oates, R. *see* Tomasi, P.A.
 Öberg, K. *see* Granberg, D.
 Odink, R.J.H. *see* Arends, N.J.T.
 Okosieme, O.E., Premawardhana, L.D.K.E., Jayasinghe, A., de Silva, D.G.H., Smyth, P.P.A., Parkes, A.B., Lejeune, P.J., Ruf, J. & Lazarus, J.H. Thyroglobulin epitope recognition in a post iodine-supplemented Sri Lankan population: 190
 Ong, K. *see* Potau, N.
 Ong, K.K. *see* Bazaes, R.A.
 Onoda, N. *see* Nagasaki, T.
 Opocher, G., Schiavi, F., Vettori, A., Pampinella, F., Vitiello, L., Calderan, A., Vianello, B., Murgia, A., Martella, M., Taccaliti, A., Mantero, F. & Mostacciulo, M.L. Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma: 707
 Ortega, E. *see* Webb, S.M.
 Oscarsson, J. *see* Leonsson, M.
 Padfield, P.L. Prevalence and role of a raised aldosterone to renin ratio in the diagnosis of primary aldosteronism: a debate on the scientific logic of the use of the ratio in practice: 422
 Paganini, C. *see* Radetti, G.
 Page, D.C. *see* Tomasi, P.A.
 Palanisamy, N. *see* Shattuck, T.M.
 Palou, A. *see* González Sánchez, J.L.
 Pampinella, F. *see* Opocher, G.
 Pang, R.W.C. *see* Tan, K.C.B.
 Panunzi, C. *see* Tonacchera, M.
 Paoloni, A. *see* Baldelli, R.
 Papamichael, C. *see* Alevizaki, M.
 Parkes, A.B. *see* Okosieme, O.E.
 Parkinson, C., Whatmore, A.J., Yates, A.P., Drake, W.M., Brabant, G., Clayton, P.E. & Trainer, P.J. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly: 168
 Pasanisi, F. *see* Mancini, F.P.
 Paschke, R. *see* Miedlich, S.
 Paterson, K. *see* McKenzie, J.
 Pattarozzi, A. *see* Florio, T.
 Pearce, S.H.S. *see* Sayer, J.A.
 Peinó, R. *see* Alvarez, P.
 Pekic, S. *see* Popovic, V.
 Pellegrino, M. *see* Giordano, R.
 Pellicano, M. *see* Tommaselli, G.A.
 Penezić, Z. *see* Žarković, M.
 Penny, A. *see* Kousta, E.
 Perri, A. *see* Tonacchera, M.
 Perrino, S. *see* De Bellis, A.
 Persani, L. *see* Fugazzola, L.
 Petrie, J.R. *see* McKenzie, J.
 Petry, C.J. *see* Bazaes, R.A.
 Philipp, T. *see* Witzke, O.
 Philippou, G. *see* Alevizaki, M.
 Phillip, M. *see* Lazar, L.
 Pierik, F.H. *see* de Gouveia Brazao, C.A.
 Pinchera, A. *see* Cecconi, E.
 Pinchera, A. *see* Tonacchera, M.
 Pinto, L.P., Hanna, F.W.F., Evans, L.M., Davies, J.S., John, R. & Scanlon, M.F. The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia: 580
 Piscopo, M. *see* Mazziotti, G.
 Pivetti, S. *see* Tassone, F.
 Pivonello, R. *see* Mattera, D.
 Placha, G. *see* Bednarczuk, T.
 Plehwe, W.E. Vitamin D deficiency in the 21st century: an unnecessary pandemic?: 22
 Podestà, F. *see* Di Blasio, A.M.
 Pols, H.A.P. *see* van Rossum, E.F.C.
 Pop, V.J., Brouwers, E.P., Vader, H.L., Vulsma, T., van Baar, A.L. & de Vijlder, J.J. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study: 282
 Popovic, V., Pekic, S., Doknic, M., Micic, D., Damjanovic, S., Zarkovic, M., Aimaretti, G., Corneli, G., Ghigo, E., Deiguez, C. & Casanueva, F.F. The effectiveness of arginine + GHRH test compared with GHRH + GHRP-6 test in diagnosing growth hormone deficiency in adults: 251
 Porretti, S. *see* Giavoli, C.
 Potau, N., Williams, R., Ong, K., Sánchez-Ufarte, C., de Zegher, F., Ibáñez, L. & Dunger, D. Fasting insulin sensitivity and post-oral glucose hyperinsulinaemia related to cardiovascular risk factors in adolescents with precocious pubarche: 756
 Powell, M. *see* Kola, B.
 Premawardhana, L.D.K.E. *see* Okosieme, O.E.
 Pritelli, C. *see* Verga, U.
 Procopio, M. *see* Cecconi, E.
 Proenza, A.M. *see* González Sánchez, J.L.
 Prummel, M.F. *see* Strieder, T.G.A.
 Puzziello, A. *see* Mattera, D.

- Radetti, G., Buzi, F., Cassar, W., Paganini, C., Stacul, E. & Maghnie, M. Growth hormone secretory pattern and response to treatment in children with short stature followed to adult height: 27
- Ramis, J.M. *see* González Sánchez, J.L.
- Ramsden, R. *see* Astuti, D.
- Ramunni, J. *see* Gianotti, L.
- Ravetti, J.L. *see* Florio, T.
- Reeser, H.M. *see* Arends, N.J.T.
- Refetoff, S. *see* Tonacchera, M.
- Reid, R. *see* Levy, A.
- Reinhardt, W. *see* Witzke, O.
- Reis, A.F. *see* Roussel, R.
- Repetto, M. *see* Abalovich, M.
- Reschini, E. *see* Fugazzola, L.
- Reutens, A.T. *see* Nugent, A.G.
- Reznek, R. *see* Kaltsas, G.A.
- Ribaudo, M.-C. *see* Baldelli, R.
- Riccardi, G. *see* Mancini, F.P.
- Robinson, S. *see* Kousta, E.
- Rojas-García, R. *see* Webb, S.M.
- Romeo, A. *see* Mazziotti, G.
- Ronchi, C.L. *see* Giavoli, C.
- Rong, R. *see* Tso, A.W.K.
- Rongen-Westerlaken, C. *see* Arends, N.J.T.
- Rose, S. *see* Shaw, N.J.
- Rossetto, R. *see* Tassone, F.
- van Rossum, E.F.C. *see* Di Blasio, A.M.
- van Rossum, E.F.C., Koper, J.W., van den Beld, A.W., Uitterlinden, A.G., Arp, P., Ester, W., Janssen, J.A.M.J.L., Brinkmann, A.O., de Jong, F.H., Grobbee, D.E., Pols, H.A.P. & Lamberts, S.W.J. Identification of the *Bcl* polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids *in vivo* and body mass index: 585
- Roussel, R., Reis, A.F., Dubois-Laforgue, D., Bellanné-Chantelot, C., Timsit, J. & Velho, G. The N363S polymorphism in the glucocorticoid receptor gene is associated with overweight in subjects with type 2 diabetes mellitus: 237
- Rovere, S. *see* Aimaretti, G.
- Rubinstein, R. *see* Krausz, Y.
- Ruf, J. *see* Okosieme, O.E.
- Rumley, A. *see* McKenzie, J.
- Russell-Jones, D.L. *see* McMillan, C.V.
- van der Saag, P.T. *see* Vermeer, H.
- Sabatino, L. *see* Mancini, F.P.
- Saccà, L., Napoli, R. & Cittadini, A. Growth hormone, acromegaly, and heart failure: an intricate triangulation: 660
- Sachs, J. *see* Krausz, Y.
- Sader, M.A., Griffiths, K.A., Skilton, M.R., Wishart, S.M., Handelsman, D.J. & Celemajer, D.S. Physiological testosterone replacement and arterial endothelial function in men: 62
- Sagiyama, K.-I. *see* Tanaka, M.
- Sakano, S. *see* Fuse, Y.
- Samanci, N. *see* Cakir, M.
- Samuelsson, G. *see* Bülow, B.
- Sánchez-Ufarte, C. *see* Potau, N.
- Sanno, N. *see* Kim, K.
- Sansone, D. *see* De Bellis, A.
- Sari, R., Balci, M.K., Altunbas, H. & Karayalcin, U. The effect of body weight and weight loss on thyroid volume and function in obese women: 258
- Sarika, H.-L. *see* Alevizaki, M.
- Sattar, N. *see* McKenzie, J.
- Savage, P. *see* Ben-Shlomo, Y.
- Sayer, J.A. & Pearce, S.H.S. Extracellular calcium-sensing receptor dysfunction is associated with two new phenotypes: 419
- Scanlon, M.F. *see* Pinto, L.P.
- Scheinowitz, M. *see* Ben-Dov, I.
- Schettini, D. *see* Florio, T.
- Schettini, G. *see* Florio, T.
- Schiavi, F. *see* Opocher, G.
- Seidl, C. *see* Badenhop, K.
- Serrano Rios, M. *see* González Sánchez, J.L.
- Serrano-Munuera, C. *see* Webb, S.M.
- de Servi, M. *see* Tonacchera, M.
- Seth, J. *see* Strachan, M.W.J.
- Shalet, S.M. *see* Lissett, C.A.
- Shalet, S.M. *see* Mukherjee, A.
- Shattuck, T.M., Kim, T.S., Costa, J., Yandell, D.W., Imanishi, Y., Palanisamy, N., Gaz, R.D., Shoback, D., Clark, O.H., Monchik, J.M., Wierman, M.E., Hollenberg, A., Tojo, K., Chaganti, R.S.K. & Arnold, A. Mutational analyses of *RB* and *BRCA2* as candidate tumour suppressor genes in parathyroid carcinoma: 180
- Shaw, N.J., Fraser, N.C., Rose, S., Crabtree, N.J. & Boivin, C.M. Bone density and body composition in children with growth hormone insensitivity syndrome receiving recombinant IGF-I: 487
- Shepherd, P.S. *see* Johnstone, A.P.
- Shibasaki, T. *see* Kim, K.
- Shimamoto, K. *see* Furuhashi, M.
- Shoback, D. *see* Shattuck, T.M.
- de Silva, D.G.H. *see* Okosieme, O.E.
- Skilton, M.R. *see* Sader, M.A.
- Skogseid, B. *see* Granberg, D.
- Smith, G.D. *see* Ben-Shlomo, Y.
- Smith, K.A. *see* Kemp, E.H.
- Smith, T.P. *see* Suliman, A.M.
- Smyth, P.P.A. *see* Okosieme, O.E.
- Solimeno, S. *see* De Bellis, A.
- Sönksen, P.H. *see* McMillan, C.V.
- Sorvillo, F. *see* Mazziotti, G.

- Spaziante, R. *see* Florio, T.
- Stacul, E. *see* Radetti, G.
- Stefanova, E. *see* Žarković, M.
- Stoddart, M. *see* Strachan, M.W.J.
- Stokvis-Brantsma, W.H. *see* Arends, N.J.T.
- Strachan, M.W.J., Teoh, W.L., Don-Wauchope, A.C., Seth, J., Stoddart, M. & Beckett, G.J. Clinical and radiological features of patients with macroprolactinaemia: 339
- Strieder, T.G.A., Prummel, M.F., Tijssen, J.G.P., Endert, E. & Wiersinga, W.M. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease: 396
- Suganuma, T. *see* Kotani, T.
- Sugiguchi, S. *see* Nagasaki, T.
- Suliman, A.M., Freaney, R., Smith, T.P., McBrinn, Y., Murray, B. & McKenna, T.J. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency: 380
- Sullivan, D. *see* Nugent, A.G.
- Šumarac-Dumanović, M. *see* Žarković, M.
- Sundin, A. *see* Granberg, D.
- Svensson, T. *see* Bülow, B.
- Swords, F.M., Carroll, P.V., Kisalu, J., Wood, P.J., Taylor, N.F. & Monson, J.P. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement: 613
- Szathmári, M., Treszl, A. & Vászárhelyi, B. Left ventricular mass index and ventricular septum thickness are associated with serum dehydroepiandrosterone-sulphate levels in hypertensive women: 110
- Taccaliti, A. *see* Opocher, G.
- Tagliaferri, M. *see* Di Blasio, A.M.
- Tahara, H. *see* Nagasaki, T.
- Tait, K.F. & Gough, S.C.L. The genetics of autoimmune endocrine disease: 1
- Takano, K. *see* Kim, K.
- Tamburrano, G. *see* Aimaretti, G.
- Tamburrano, G. *see* Baldelli, R.
- Tan, K.C.B. *see* Tso, A.W.K.
- Tan, K.C.B., Pang, R.W.C., Tiu, S.C. & Lam, K.S.L. Effects of treatment with Sandostatin® LAR® on small dense LDL and remnant-like lipoproteins in patients with acromegaly: 558
- Tanaka, K., Towata, S., Nakao, K., Mizuguchi, H., Hayakawa, T., Niwa, M., Ishii, N. & Nagayama, Y. Thyroid cancer immunotherapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model: 734
- Tanaka, M., Tatebe, Y., Nakahara, T., Yasuhara, D., Sagiya, K.-I., Muranaga, T., Ueno, H., Nakazato, M., Nozoe, S.-I. & Naruo, T. Eating pattern and the effect of oral glucose on ghrelin and insulin secretion in patients with anorexia nervosa: 574
- Tandon, N. *see* Marwaha, R.K.
- Tassone, F., Lanfranco, F., Gianotti, L., Pivetti, S., Navone, F., Rossetto, R., Grottoli, S., Gai, V., Ghigo, E. & Maccario, M. Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables: 374
- Tatebe, Y. *see* Tanaka, M.
- Taylor, N.F. *see* Swords, F.M.
- Teh, B.T. *see* Tso, A.W.K.
- Teoh, W.L. *see* Strachan, M.W.J.
- Teramoto, A. *see* Kim, K.
- Thellung, S. *see* Florio, T.
- Thomas, G.N. *see* Ma, Y.Q.
- Tijssen, J.G.P. *see* Strieder, T.G.A.
- Timsit, J. *see* Roussel, R.
- Tiu, S.C. *see* Tan, K.C.B.
- Tiu, S.C. *see* Tso, A.W.K.
- Tojo, K. *see* Shattuck, T.M.
- Tomasi, P.A., Oates, R., Brown, L., Delitala, G. & Page, D.C. The pituitary-testicular axis in Klinefelter's syndrome and in oligo-azoospermic patients with and without deletions of the Y chromosome long arm: 214
- Tomlinson, B. *see* Ma, Y.Q.
- Tommaselli, G.A., Di Carlo, C., Bifulco, G., Di Spiezio Sardo, A., Pellicano, M. & Nappi, C. Serum leptin levels in patients with premenstrual syndrome treated with GnRH analogues alone and in association with tibolone: 716
- Tonacchera, M., Agretti, P., De Marco, G., Elisei, R., Perri, A., Ambrogini, E., de Servi, M., Ceccarelli, C., Viacava, P., Refetoff, S., Panunzi, C., Bitti, M.L.M., Vitti, P., Chiovato, L. & Pinchera, A. Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein: 500
- Torres, N. *see* Elias, P.C.L.
- Tosoni, P. *see* Zoico, E.
- Towata, S. *see* Tanaka, K.
- Trainer, P.J. *see* Parkinson, C.
- Travaglini, P. *see* Giavoli, C.
- Treszl, A. *see* Szathmári, M.
- Trimarchi, F. *see* Vermiglio, F.
- Trischitta, V. *see* Baldelli, R.
- Tso, A.W.K., Rong, R., Lo, C.Y., Tan, K.C.B., Tiu, S.C., Wat, N.M.S., Xu, J.Y., Villablanca, A., Larsson, C., Teh, B.T. & Lam, K.S.L. Multiple endocrine neoplasia type 1 (MEN1): genetic and clinical analysis in the Southern Chinese: 129
- Turner, M. *see* Weedon, M.N.
- Ueda, M. *see* Nagasaki, T.
- Ueno, H. *see* Tanaka, M.
- Uitterlinden, A.G. *see* van Rossum, E.F.C.
- Umeki, K. *see* Kotani, T.

- Umenai, T. *see* Fuse, Y.
 Ura, N. *see* Furuhashi, M.
 Vaccaro, O. *see* Mancini, F.P.
 Vader, H.L. *see* Pop, V.J.
 Vannucchi, G. *see* Fugazzola, L.
 Vászárhelyi, B. *see* Szathmári, M.
 Veldhuis, J.D. *see* Gianotti, L.
 Velho, G. *see* Roussel, R.
 Verga, U., Fugazzola, L., Cambiaghi, S., Pritelli, C., Alessi, E., Cortelazzi, D., Gangi, E. & Beck-Peccoz, P. Frequent association between MEN 2A and cutaneous lichen amyloidosis: 156
 Verma, K. *see* Marwaha, R.K.
 Vermeer, H., Hendriks-Stegeman, B.I., van den Brink, C.E., van der Saag, P.T., van der Burg, B., van Buul-Offers, S.C. & Jansen, M. A novel specific bioassay for the determination of glucocorticoid bioavailability in human serum: 49
 Vermiglio, F., Lo Presti, V.P., Violi, M.A., Moleti, M., Castagna, M.G., Finocchiaro, M.D., Mattina, F., Mandolino, M., Zimbaro, G. & Trimarchi, F. Changes in both size and cytological features of thyroid nodule after levothyroxine treatment: 347
 Vestergaard, P. *see* Gravholt, C.H.
 Vettor, R. *see* Zoico, E.
 Vettori, A. *see* Opocher, G.
 Viacava, P. *see* Tonacchera, M.
 Vianello, B. *see* Opocher, G.
 de Vijlder, J.J. *see* Pop, V.J.
 Villa, V. *see* Florio, T.
 Villablanca, A. *see* Tso, A.W.K.
 Violi, M.A. *see* Vermiglio, F.
 Vitiello, L. *see* Opocher, G.
 Vitti, P. *see* Tonacchera, M.
 Vreken, P. *see* Assies, J.
 Vulsma, T. *see* Pop, V.J.
 Waelkens, J.J.J. *see* Arends, N.J.T.
 Wagner, R. *see* Ben-Dov, I.
 Wall, J.R. *see* De Bellis, A.
 Wallymahmed, M. *see* Malik, I.A.
 Wat, N.M.S. *see* Tso, A.W.K.
 Watson, P.F. *see* Kemp, E.H.
 Webb, S.M., de Andrés-Aguayo, I., Rojas-García, R., Ortega, E., Gallardo, E., Mestrón, A., Serrano-Munuera, C., Casamitjana, R. & Illa, I. Neuromuscular dysfunction in adult growth hormone deficiency: 450
 Weber, G. *see* Fugazzola, L.
 Weber, R.F.A. *see* de Gouveia Brazao, C.A.
 Weedon, M.N., Turner, M., Knight, B., Clark, P., Hattersley, A.T. & Frayling, T.M. Variants in the aromatase gene and on the Y-chromosome are not associated with adult height or insulin resistance in a UK population: 175
 Weetman, A.P. *see* Kemp, E.H.
 Westlin, J.-E. *see* Granberg, D.
 Westwood, M. *see* Whatmore, A.J.
 Whatmore, A.J. *see* Parkinson, C.
 Whatmore, A.J., Hall, C.M., Jones, J., Westwood, M. & Clayton, P.E. Ghrelin concentrations in healthy children and adolescents: 649
 Wierman, M.E. *see* Shattuck, T.M.
 Wiersinga, W.M. *see* Strieder, T.G.A.
 Wiklund, O. *see* Leonsson, M.
 Wikstrand, J. *see* Leonsson, M.
 Wilding, J.P.H. *see* Malik, I.A.
 Williams, R. *see* Potau, N.
 Winterhagen, T. *see* Witzke, O.
 Wishart, S.M. *see* Sader, M.A.
 Witzke, O., Winterhagen, T., Kribben, A., Philipp, T., Mann, K. & Reinhardt, W. Interleukin-2 given to asymptomatic HIV-infected individuals leads to an exaggerated response of the pituitary gland to the action of CRH: 104
 Wood, P.J. *see* Swords, F.M.
 Woodroffe, M.N. *see* Kemp, E.H.
 Xu, J.Y. *see* Tso, A.W.K.
 Yamada, C. *see* Fuse, Y.
 Yandell, D.W. *see* Shattuck, T.M.
 Yasufuku-Takano, J. *see* Kim, K.
 Yasuhara, D. *see* Tanaka, M.
 Yates, A.P. *see* Parkinson, C.
 Young, J. *see* Gussi, I.-L.
 Yu, L. *see* Nigam, R.
 Zadik, Z. Physiological but not pharmacological growth hormone tests predict adult height: 25
 Zamboni, M. *see* Zoico, E.
 Žarković, M., Stefanova, E., Cirić, J., Penezić, Z., Kostić, V., Šumarac-Dumanović, M., Macut, D., Ivović, M.S. & Gligorović, P.V. Prolonged psychological stress suppresses cortisol secretion: 811
 Zarkovic, M. *see* Popovic, V.
 de Zegher, F. *see* Potau, N.
 Zettinig, G., Asenbaum, S., Fueger, B.J., Hofmann, A., Diemling, M., Mittlboeck, M. & Dudczak, R. Increased prevalence of subclinical brain perfusion abnormalities in patients with autoimmune thyroiditis: evidence of Hashimoto's encephalitis?: 637
 Zimbaro, G. *see* Vermiglio, F.
 Zoico, E., Zamboni, M., Adami, S., Vettor, R., Mazzali, G., Tosoni, P., Bissoli, L. & Bosello, O. Relationship between leptin levels and bone mineral density in the elderly: 97

Subject Index to Volume 59

- Acipimox
 plasma FFA reduction in diabetes mellitus type 1 431
- Acromegaly
 acromegalic features after GH therapy 788
 effects of Sandostatin® LAR® on lipoproteins 558
 GH and heart failure (Review) 660
 IGF-I normalization and leptin in 168
 somatostatin analogues treatment 492
- ACTH syndrome
 occult ectopic, PET scan (Letter) 404
- Addison's disease
 adrenal antibodies in 593
- Adenoviral vectors
 model of thyroid cancer immunotherapy 734
- Adipocytokines
 in thyroid dysfunction 621
- Adolescents
 ghrelin concentrations 649
 insulin, cardiovascular disease risk and precocious
 pubarche 756
- Adrenal antibodies
 in Addison's disease 593
- Adrenal insufficiency
 glucocorticoid replacement and bone turnover 380
- Adrenal testing
 venous catheterization and hyperandrogenism 34
- Adrenoleucodystrophy, X-linked
 DHEA treatment 459
- Aldosterone to renin ratio
 in diagnosis of primary aldosteronism (Commentaries)
 422, 427
- Aldosteronism, primary
 aldosterone to renin ratio (Commentaries) 422, 427
- Alprazolam
 in neuroendocrine response to hypoglycaemia 314
- Alzheimer's disease
 concerns surrounding HRT (Review) 145
- Androgens
 androgen receptor gene CAG polymorphism, and CAD
 749
 endocrine intervention for transsexuals (Review) 409
- Anorexia nervosa
 effect of glucose on ghrelin 574
- Anti-androgens
 endocrine intervention for transsexuals (Review) 409
- Antibodies
 adrenal, in Addison's disease 593
 monoclonal, TSH receptor functional site 437
- Apnoea
 obstructive sleep apnoea syndrome 374
- Arginine
 in combined provocative tests for GHD 251
- Atherosclerosis
 PPAR γ and human genetic variants (Review) 267
- Autoantibodies
 thyroglobulin 190
- Autoimmune disease
 genetics (Review) 1
- Autoimmune regulator (AIRE1) gene
 in autoimmune endocrine disease (Review) 1
- Autoimmune thyroid disease
 baseline characteristics of female relatives 396
 chemokine expression 207
- Autoimmune thyroiditis
 brain perfusion in 637
- Autoimmunity
 CTLA-4 variants in Graves' disease (Commentary) 555
 eye, in Graves' ophthalmopathy 388
 residual goitre, postiodization 672
- Blood pressure
 DHEAS and left ventricular mass 110
 glucocorticoid receptor gene and obesity 68
- BMI
 glucocorticoid receptor gene and obesity 68
 glucocorticoid receptor polymorphism 585
- Body composition
 in GH insensitivity syndrome 487
- Bone
 BMD in GH insensitivity syndrome 487
 BMD and leptin in the elderly 97
 BMD and maturation in short SGA children 779
 endocrine intervention for transsexuals (Review) 409
 fracture rates in Turner's syndrome 89
 metabolism, concerns surrounding HRT (Review) 145
 turnover, and glucocorticoid replacement schedules
 380
 vitamin D deficiency (Commentary) 22
- Brain
 endocrine intervention for transsexuals (Review) 409
 fetus, development, and thyroid hormones
 (Commentary) 280
 perfusion, in autoimmune thyroiditis 637
- Breast
 endocrine intervention for transsexuals (Review) 409
 cancer, concerns surrounding HRT (Review) 145

- Bronchial carcinoid tumours
 - octreoscan 793
- Carcinoid tumours
 - bronchial, octreoscan 793
- Cardiovascular disease
 - androgens in coronary artery disease 749
 - concerns surrounding HRT (Review) 145
 - GH, acromegaly and heart failure (Review) 660
 - insulin exposure and precocious pubarche 756
 - low-dose combined HRT 682
 - pituitary, intima-media thickness and inflammatory markers 242
 - PPAR γ and human genetic variants (Review) 267
- CHD
 - concerns surrounding HRT (Review) 145
- Chemokines
 - expression in autoimmune thyroid disease 207
- Children
 - body composition and BMD in GH insensitivity syndrome 487
 - effects of hypothyroxinaemia during pregnancy 282
 - ghrelin concentrations 649
 - GH tests and adult height 27, (Commentary) 25
 - GH therapy and hypothyroidism 806
 - GH therapy for syndromic disorders (Review) 12
 - growth, IGF-I and IGFBP-3 366
 - INSVNTR*, insulin sensitivity and secretion in infancy 599
 - iodine deficiency disorders in Mongolia 298
 - short SGA, and GH therapy 779
- Cholesterol
 - glucocorticoid receptor gene and obesity 68
 - HDL, apoA-I gene, obesity and early-onset diabetes 442
- Chromogranin A
 - pituitary adenomas 644
- Cognition
 - concerns surrounding HRT (Review) 145
- Colon cancer
 - concerns surrounding HRT (Review) 145
- Coronary artery disease
 - androgen receptor gene CAG polymorphism 749
- Cortisol
 - in differential diagnosis of Cushing's syndrome 800
 - metabolic syndrome in South Indians (Letter) 405
 - suppression, in prolonged psychological stress 811
- CPHD
 - growth without GH 82
- CRH
 - response to IL-2 in HIV infection 104
- Cryptorchidism
 - inhibin B in subfertile men 136
- CT
 - bronchial carcinoid tumours 793
 - SPECT/CT hybrid imaging of neuroendocrine tumours 565
- CTLA-4 gene
 - in autoimmune endocrine disease (Review) 1
 - variants in Graves' disease (Commentary) 555
- Cushing's disease/syndrome
 - differential diagnosis 800
- Cutaneous lichen amyloidosis (CLA)
 - in MEN 2A 156
- Cytology
 - changes in thyroid nodules after thyroxine treatment 347
- Dexamethasone suppression test
 - differential diagnosis of Cushing's syndrome 800
- DHEA(S)
 - left ventricular mass in women 110
 - treatment of X-linked adrenoleucodystrophy 459
- Diabetes insipidus
 - familial autosomal neurohypophyseal (FNDI), vasopressin secretion 511
- Diabetes mellitus
 - type 1, effect of plasma FFA reduction 431
 - type 2, early onset and apoA-I gene 442
 - type 2, Gln27Glu₂-AR polymorphism 476
 - type 2 (gestational), insulin action and secretion 289
 - type 2, glucocorticoid receptor gene and overweight 237
 - type 2, and HRT 657
 - type 2, PPAR γ and human genetic variants (Review) 267
- Domperidone
 - TSH response in macroprolactinaemia 580
- Dopamine agonists
 - withdrawal policy, and prolactinomas (Letter) 406
- Dyslipidaemia
 - PPAR γ and human genetic variants (Review) 267
- Eating disorders see Anorexia nervosa
- E-cadherin
 - in pituitary adenomas 768
- Elderly people
 - BMD and leptin 97
 - GHBP and leptin 482
 - glucocorticoid receptor polymorphism 585
- Encephalitis, Hashimoto's 637
- Endometrial cancer
 - concerns surrounding HRT (Review) 145
- Endothelial function
 - testosterone replacement in men 62

- Endothelin-1
expression in thyroid carcinoma 354
- Epidemiology
iodine deficiency disorders in Mongolia 298
- Exercise
reduced capacity in Laron syndrome 763
- Fatty acids
in DHEA treatment of X-linked adrenoleucodystrophy 459
free (FFA), reduction in diabetes mellitus type 1 431
- Fertility
cryptorchidism and inhibin B 136
endocrine intervention for transsexuals (Review) 409
testicular function in Y-deleted and Klinefelter's patients 214
- Fetus
growth, IGF-I and IGFBP-3 366
thyroid hormones and neurodevelopment 282, (Commentary) 280
- Fibrous bodies
in pituitary adenomas 768
- Fractures
in Turner's syndrome 89
- Gastrointestinal stromal tumour (GIST)
hypoglycaemia with (Letter) 402
- Gender
dysphoria, endocrine intervention for transsexuals (Review) 409
see also Men; Women
- Genetics
androgen receptor gene CAG polymorphism, and CAD 749
apoA-I gene, obesity and early-onset diabetes 442
autoimmune endocrine disease (Review) 1
chemokine expression in autoimmune thyroid disease 207
CTLA-4 variants in Graves' disease (Commentary) 555
cutaneous lichen amyloidosis in MEN 2A 156
CYP19, Y-RFLP and adult height 175, (Commentary) 278
familial autosomal neurohypophyseal diabetes insipidus (FNDI) 511
familial male-limited precocious puberty (Letter) 533
GH and IGF-I receptors in somatotroph adenomas 328
Gln27Glu₂-AR polymorphism and obesity-related disorders 476
glucocorticoid receptor gene and obesity 68
glucocorticoid receptor gene and overweight 237
glucocorticoid receptor polymorphism 585
IL-13 gene polymorphisms in Graves' disease 519
INSVNTR, insulin sensitivity and secretion in infancy 599
MEN1 in Southern Chinese people 129
NIS deletion and congenital hypothyroidism 500
novel mutation in steroid sulphatase deficiency (Letter) 263
partial thyroxine-binding globulin deficiency (Letter) 824
pathogenesis of autoimmune thyroid disease 396
PPAR γ and metabolism (Review) 267
primary hyperparathyroidism (Review) 539
RB and BRCA2 in parathyroid cancer 180
short arm of chromosome 1 in pheochromocytoma 707
susceptibility to paraganglioma and pheochromocytoma 728
testicular function in Y-deleted and Klinefelter's patients 214
TPO gene mutation 198
uncoupling protein-2 gene, obesity and PPAR γ 2 817
- GH
acromegaly and heart failure (Review) 660
E-cadherin and fibrous bodies in pituitary adenomas 768
intracellular mechanisms in pituitary adenomas 115
plasma FFA reduction in diabetes mellitus type 1 431
psychological effects of withdrawal in adult GHD 467
receptors in somatotroph adenomas 328
resistance, and reduced exercise capacity 763
secretagogue receptor, in pituitary adenomas 630
secretion in familial hypercalcaemia 604
status, and glucocorticoid exposure 613
tests, in prediction of adult height 27, (Commentary) 25
therapy, acromegalic features 788
therapy, hypothyroidism in children with GHD 806
therapy, and quality of life 75
therapy in short SGA children 779
therapy, for syndromic disorders (Review) 12
- GHBP
- GHD
leptin and, in the elderly 482
- GHD
age at onset and IGF-I status 773
combined provocative tests in diagnosis 251
diagnostic sensitivity of IGF-I measurement 56
growth without GH in CPHD 82
intima-media thickness and inflammatory markers 242
neuromuscular dysfunction 450
psychological effects of withdrawal of GH 467
quality of life in GH-treated patients 75
- GH insensitivity syndrome
IGF-I therapy and body composition 487

- Ghrelin
 - in children and adolescents 649
 - effect of glucose in anorexia nervosa 574
 - in pituitary adenomas 630
- GHRH
 - in combined provocative tests for GHD 251
 - plasma FFA reduction in diabetes mellitus type 1 431
- GHRP-6
 - in combined provocative tests for GHD 251
- Glucocorticoid
 - bioavailability assay 49
 - effect of exposure on GH status 613
 - receptor gene and obesity 68
 - receptor gene and overweight 237
 - receptor polymorphism 585
 - replacement, and bone turnover 380
 - therapy, in Graves' ophthalmopathy 388
- Glucose
 - effect on ghrelin and insulin in anorexia nervosa 574
 - homeostasis, Gln27Glu₂-AR polymorphism and obesity-related disorders 476
 - homeostasis, post-GDM 289
 - homeostasis, PPAR γ and human genetic variants (Review) 267
 - homeostasis, somatostatin analogue treatment of acromegaly 492
 - metabolism, and HRT (Letter) 657
- GM-CSF
 - in thyroid cancer immunotherapy 734
- GnRH
 - analogues in treatment of PMS 716
 - GnRH antagonist and gonadotrophin pulsatility in women 526
- Goitre
 - iodine deficiency disorders in Mongolia 298
 - residual, in postiodization phase 672
- Grapefruit juice
 - inhibition of 11 β -hydroxysteroid dehydrogenase (Letter) 143
- Graves' disease
 - CTLA-4 variants in (Commentary) 555
 - IL-13 gene polymorphisms 519
 - markers of eye autoimmunity 388
 - oxidative stress in 321
 - TSH receptor functional site 437
- Hashimoto's encephalitis
 - brain perfusion 637
- Hashimoto's thyroiditis
 - ultrasound examination 223
- Heart function
 - DHEAS and left ventricular mass 110
 - endocrine intervention for transsexuals (Review) 409
 - GH, acromegaly and heart failure (Review) 660
 - VIP in chronic heart failure 723
- Height
 - adult, CYP19 and Y-chromosome variants 175, (Commentary) 278
 - adult, GH tests in prediction 27, (Commentary) 25
 - growth without GH in CPHD 82
 - IFG-1 and IGFBP-3 in growth patterns 366
 - see also Stature, short
- Hepatocellular carcinoma
 - IGF-I:IGFBP-3 ratio 699
- HIV infection
 - IL-2 and CRH responses 104
- HRT
 - concerns surrounding (Review) 145, (Letter) 657
 - glucose metabolism and (Letter) 657
 - low-dose combined, and cardiovascular risk 682
- Hydrocortisone
 - therapy in hypopituitarism 613
- 11 β -Hydroxysteroid dehydrogenase
 - inhibition by grapefruit juice (Letter) 143
- Hyperandrogenism
 - venous catheterization and sampling 34
- Hypercalcaemia
 - familial hypocalciuric, and GH secretion 604
- Hyperinsulinaemia
 - cardiovascular disease risk and precocious pubarche 756
- Hyperparathyroidism
 - primary, genetic and clinical aspects (Review) 539
 - with thyroid carcinoma (Letter) 823
- Hyperprolactinaemia
 - TSH response to domperidone 580
- Hypertension
 - DHEAS and left ventricular mass 110
 - essential, resistin levels in 507
 - in primary aldosteronism (Commentaries) 422, 427
- Hyperthyroidism
 - adipocytokines in 621
- Hypoglycaemia
 - alprazolam in neuroendocrine response 314
 - with gastrointestinal stromal tumour (Letter) 402
- Hypogonadism
 - hypogonadotropic, free α -subunit in diagnosis 307
- Hyponatraemia
 - euvolaemic, treatment (Letter) 142
- Hypopituitarism
 - diagnostic sensitivity of IGF-I measurement 56
 - glucocorticoid exposure and GH status 613

- hypothalamic-pituitary axis disease and acquired prolactin deficiency 743
- Hypothalamic-pituitary axis
 - disease, and acquired prolactin deficiency 743
- Hypothalamic-pituitary-adrenal (HPA) axis
 - prolonged psychological stress and 811
- Hypothalamus-pituitary-thyroid axis
 - GH therapy in children with GHD 806
- Hypothyroidism
 - adipocytokines in 621
 - congenital, NIS deletion 500
 - congenital, TSH testing 230
 - effect of thyroxine on intima-media thickness 607
 - GH therapy in children with GHD 806
 - musculoskeletal disorders in 162
 - permanent primary congenital, diagnosis and aetiology 361
 - thyroxine replacement and psychological well-being (Letter) 264
 - TPO gene mutation 198
- Hypothyroxinaemia
 - during pregnancy 282
- Hypovolaemia
 - in untreated pituitary deficiency (Letter) 535
- Ichthyosis
 - novel mutation in steroid sulphatase deficiency (Letter) 263
- IGFBP-3
 - IGF-I:IGFBP-3 ratio in hepatocellular carcinoma 699
 - in patterns of growth 366
- IGF-I
 - deficiency, and reduced exercise capacity 763
 - determinants of status in GHD 773
 - diagnostic sensitivity in panhypopituitarism 56
 - GH, acromegaly and heart failure (Review) 660
 - IGF-I:IGFBP-3 ratio in hepatocellular carcinoma 699
 - normalization in acromegaly 168
 - in patterns of growth 366
 - receptors, in somatotroph adenomas 328
 - therapy in GH insensitivity syndrome 487
- Immunotherapy
 - rat model of thyroid cancer 734
- Inflammatory markers
 - intima-media thickness and pituitary deficiency 242
- Inhibins
 - inhibin B and cryptorchidism 136
- Insulin
 - action and secretion post-GDM 289
 - cardiovascular disease risk and precocious pubarche 756
 - effect of glucose in anorexia nervosa 574
 - gene, in autoimmune endocrine disease (Review) 1
 - INSVNTR*, sensitivity and secretion in infancy 599
 - resistance, *CYP19*, Y-RFLP and adult height 175
 - resistance, in obstructive sleep apnoea syndrome 374
 - resistance, somatostatin analogues in acromegaly 492
 - sensitivity, and glucocorticoid replacement 380
 - sensitivity, PPAR γ and human genetic variants (Review) 267
- Interleukins
 - IL-2, CRH response in HIV infection 104
 - IL-6, intima-media thickness and pituitary deficiency 242
 - IL-12 in thyroid cancer immunotherapy 734
 - IL-13 gene polymorphisms in Graves' disease 519
- Intima-media thickness
 - pituitary deficiency and inflammatory markers 242
- thyroxine therapy in hypothyroidism 607
- Iodide transport defect (ITD)
 - NIS deletion and congenital hypothyroidism 500
- Iodine
 - 131 iodine treatment in Graves' disease 321
 - deficiency disorders in Mongolia 298
 - status, and residual goitre 672
 - supplementation, thyroglobulin epitope recognition 190
- Kidney
 - protein binding and elimination of leptin 44
- Klinefelter's syndrome
 - pituitary-testicular axis 214
- Lanreotide
 - intracellular mechanisms in pituitary adenomas 115
- Laron syndrome
 - reduced exercise capacity 763
- Leptin
 - BMD in the elderly 97
 - GHBP and, in the elderly 482
 - IGF-I normalization in acromegaly 168
 - in PMS 716
 - protein binding and renal elimination 44
- LH
 - GnRH antagonist and gonadotrophin pulsatility in women 526
 - receptor gene in familial male-limited precocious puberty (Letter) 533
- Lipids
 - metabolism, PPAR γ and human genetic variants (Review) 267
- Lipoproteins
 - effects of Sandostatin® LAR® in acromegaly 558

- Liver function
 - endocrine intervention for transsexuals (Review) 409
 - modulatory effects of progestogens 690
- Macroprolactinaemia
 - clinical and radiological features 339
 - TSH response to domperidone 580
- Men
 - androgens in coronary artery disease 749
 - cryptorchidism and inhibin B 136
 - Gln27Glu₂-AR polymorphism and obesity-related disorders 476
 - spinal cord injured (Letter) 534
 - testosterone replacement and endothelial function 62
- Menopause
 - concerns surrounding HRT (Review) 145
- Metabolic syndrome
 - cortisol and, in South Indians (Letter) 405
- Metabolism
 - PPAR γ and human genetic variants (Review) 267
- Methimazole
 - treatment in Graves' disease 321
- MHC-HLA genes
 - in autoimmune endocrine disease (Review) 1
- Multiple endocrine neoplasia (MEN)
 - type 1, in Southern Chinese people 129
 - type 2A, and cutaneous lichen amyloidosis 156
- Musculoskeletal system
 - disorders in thyroid disease 162
- Neurodevelopment
 - fetal, and thyroid hormones 282, (Commentary) 280
- Neuroendocrine response
 - to hypoglycaemia 314
- Neuroendocrine tumours
 - SPECT/CT hybrid imaging 565
- Neuroimaging
 - features of macroprolactinaemia 339
- Neuromuscular dysfunction
 - in adult GHD 450
- Noonan's syndrome
 - GH therapy (Review) 12
- Obesity
 - apoA-I gene and early-onset diabetes 442
 - Gln27Glu₂-AR polymorphism 476
 - glucocorticoid receptor gene 68
 - obstructive sleep apnoea syndrome 374
 - thyroid volume change in women 258
 - uncoupling protein-2 gene and PPAR γ 2 817
- Octreoscan
 - bronchial carcinoid tumours 793
- Oestrogen
 - concerns surrounding HRT (Review) 145
 - endocrine intervention for transsexuals (Review) 409
 - modulatory effects of progestogens 690
- Ophthalmopathy, Graves'
 - markers of eye autoimmunity 388
- Osteoporosis
 - concerns surrounding HRT (Review) 145
- Ovarian cancer
 - concerns surrounding HRT (Review) 145
- Ovarian function
 - endocrine intervention for transsexuals (Review) 409
 - venous catheterization and hyperandrogenism 34
- Oxidative stress
 - in Graves' disease 321
- Paraganglioma
 - genetic analysis of susceptibility 728
- Parathyroid tumours
 - genetic and clinical aspects (Review) 539
 - RB* and *BRCA2* in 180
- Pegvisomant
 - IGF-1 and leptin in acromegaly 168
- PET scan
 - occult ectopic ACTH syndrome (Letter) 404
- Phaeochromocytoma
 - genetic analysis of susceptibility 728
 - short arm of chromosome 1 in 707
- Pituitary adenomas
 - chromogranin A 644
 - E-cadherin and fibrous bodies 768
 - GH and IGF-I receptors 328
 - ghrelin and G protein α subunit 630
 - intracellular mechanisms activated by somatostatin receptors 115
- Pituitary disease
 - growth without GH in CPHD 82
 - hypovolaemia in untreated deficiency (Letter) 535
 - intima-media thickness and inflammatory markers 242
- Pituitary function
 - endocrine intervention for transsexuals (Review) 409
- Pituitary-testicular axis
 - in Y-deleted and Klinefelter's patients 214
- PPAR γ
 - metabolism and human genetic variants (Review) 267
 - PPAR γ 2, uncoupling protein-2 gene and obesity 817
- Prader-Willi syndrome
 - GH therapy (Review) 12

- Pregnancy
 - gestational diabetes 289
 - maternal hypothyroxinaemia 282
- Premenstrual syndrome (PMS)
 - leptin in 716
- Progestogens
 - effects on hepatic endocrine function 690
 - endocrine intervention for transsexuals (Review) 409
- Prolactin
 - acquired deficiency, and HPA disease 743
- Prolactinoma
 - dopamine agonist withdrawal policy (Letter) 406
- Prostate cancer
 - endocrine intervention for transsexuals (Review) 409
- Psychiatric factors
 - endocrine intervention for transsexuals (Review) 409
- Psychological factors
 - cortisol suppression with prolonged stress 811
 - GH withdrawal in adult GHD 467
 - well-being and thyroxine replacement (Letter) 264
- Pubarche, precocious
 - insulin and cardiovascular disease risk 756
- Puberty
 - delayed, differentiation 307
 - precocious, familial male-limited (Letter) 533
- Quality of life
 - in GH-treated patients 75
- Radiology
 - features of macroprolactinaemia 339
- Rat model
 - thyroid cancer immunotherapy 734
- Renin
 - aldosterone to renin ratio and primary aldosteronism (Commentaries) 422, 427
- Resistin
 - levels in essential hypertension 507
- Retroviral vectors
 - model of thyroid cancer immunotherapy 734
- Sandostatin® LAR®
 - effects on lipoproteins in acromegaly 558
- Scintigraphy
 - diagnosis of congenital hypothyroidism 361
 - hyperparathyroidism with thyroid carcinoma (Letter) 823
 - octreoscan of bronchial carcinoid tumours 793
 - SPECT/CT hybrid imaging of neuroendocrine tumours 565
- Semen
 - quality, in spinal cord injured men (Letter) 534
- Sleep
 - obstructive sleep apnoea syndrome 374
- Sodium
 - treatment of euvolaemic hyponatraemia (Letter) 142
- Sodium/iodide symporter (NIS) protein
 - in congenital hypothyroidism 500
- Somatostatin
 - intracellular mechanisms in pituitary adenomas 115
- Somatostatin analogues
 - effects of Sandostatin® LAR® on lipoproteins in acromegaly 558
 - treatment in acromegaly 492
- Somatotroph adenomas
 - GH and IGF-I receptors 328
- SPECT
 - brain perfusion in autoimmune thyroiditis 637
 - SPECT/CT hybrid imaging of neuroendocrine tumours 565
- Spinal cord injury
 - endocrine profiles and semen quality (Letter) 534
- Stature, short
 - GH tests and adult height 27, (Commentary) 25
 - GH therapy in syndromic disorders (Review) 12
 - SGA children and GH therapy 779
- Steroid sulphatase deficiency
 - novel mutation (Letter) 263
- Stress
 - prolonged, and cortisol suppression 811
- Syndromic disorders
 - GH therapy (Review) 12
- Testicular function
 - in Y-deleted and Klinefelter's patients 214
- Testosterone
 - replacement, and endothelial function 62
- Thiocyanate
 - exposure, and residual goitre 672
- Thyroglobulin
 - epitope recognition 190
 - in evaluation of thyroid nodules (Letter) 657
- Thyroid carcinoma
 - papillary, with hyperparathyroidism (Letter) 823
 - papillary, expression of endothelin-1 354
 - rat model of immunotherapy 734
- Thyroid function
 - adipocytokines in dysfunctional states 621
 - chemokine expression in autoimmune disease 207
 - disorders of, and musculoskeletal dysfunction 162
 - effect of thyroxine on intima-media thickness 607
 - fetal brain development 282, (Commentary) 280

- iodine deficiency disorders in Mongolia 298
- pathogenesis of autoimmune thyroid disease 396
- TPO gene mutation 198
- volume change in obese women 258
- Thyroid nodules
 - changes after thyroxine treatment 347
 - thyroglobulin in evaluation (Letter) 657
- Thyroid peroxidase (TPO)
 - gene mutation 198
- Thyrotoxicosis
 - musculoskeletal disorders in 162
- Thyroxine
 - effect on intima-media thickness 607
 - partial thyroxine-binding globulin deficiency (Letter) 824
 - replacement in congenital hypothyroidism 230
 - replacement, and psychological well-being (Letter) 264
 - treatment, changes in thyroid nodules 347
- Tibolone
 - in treatment of PMS 716
- T lymphocytes
 - in Graves' disease (Commentary) 555
- Transsexuals
 - endocrine intervention (Review) 409
- Triiodothyronine (T3)
 - fetal brain development and (Commentary) 280
- TSH
 - domperidone test in macroprolactinaemia 580
 - receptor, functional site 437
 - receptor gene, in autoimmune endocrine disease (Review) 1
 - testing, in congenital hypothyroidism 230
- Turner's syndrome
 - fracture rates 89
 - GH therapy (Review) 12
- Ultrasound
 - diagnosis of congenital hypothyroidism 361
 - in Hashimoto's thyroiditis 223
- Vascular disease
 - concerns surrounding HRT (Review) 145
- Vasoactive intestinal peptide (VIP)
 - in chronic heart failure 723
- Vasopressin
 - secretion in familial autosomal neurohypophyseal diabetes insipidus 511
- Venous catheterization
 - in hyperandrogenism 34
- Venous thromboembolism
 - concerns surrounding HRT (Review) 145
 - endocrine intervention for transsexuals (Review) 409
- Vitamin D
 - deficiency (Commentary) 22
 - receptor gene, in autoimmune endocrine disease (Review) 1
- Weight
 - glucocorticoid receptor gene and overweight 237
 - thyroid volume change in obese women 258
 - see also Obesity
- Women
 - concerns surrounding HRT (Review) 145
 - Gln27Glu₂-AR polymorphism and obesity-related disorders 476
 - GnRH antagonist and gonadotrophin pulsatility 526
 - hypertensive, DHEAS and left ventricular mass 110
 - hypothyroxinaemia during pregnancy 282
 - insulin action and secretion post-GDM 289
 - iodine deficiency disorders in Mongolia 298
 - low-dose combined HRT and cardiovascular risk 682
 - pathogenesis of autoimmune thyroid disease 396
 - postmenopausal, modulatory effects of progestogens 690
 - thyroid volume change in obesity 258
 - venous catheterization and hyperandrogenism 34
- Y-chromosome
 - CYP19, and adult height 175

